| 3.6545 0.105 (2.94%) | 04-23 10:46 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.62 | 1-year : | 4.96 |
| Resists | First : | 3.95 | Second : | 4.25 |
| Pivot price | 3.76  |
|||
| Supports | First : | 3.48 | Second : | 2.89 |
| MAs | MA(5) : | 3.61 |
MA(20) : | 3.79 |
| MA(100) : | 10.64 |
MA(250) : | 19.29 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 13.1 |
D(3) : | 15.7 |
| RSI | RSI(14): 39.1 |
|||
| 52-week | High : | 61.2 | Low : | 3.48 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TENX ] has closed above bottom band by 25.6%. Bollinger Bands are 92.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.66 - 3.69 | 3.69 - 3.7 |
| Low: | 3.49 - 3.51 | 3.51 - 3.53 |
| Close: | 3.52 - 3.56 | 3.56 - 3.59 |
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Mon, 11 Mar 2024
Should You Accumulate Tenax Therapeutics Inc (TENX) Stock Monday Morning? - InvestorsObserver
Thu, 29 Feb 2024
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024 - Yahoo Finance
Tue, 20 Feb 2024
Tenax Therapeutics Amends Global Rights Deal with Orion - TipRanks.com - TipRanks
Mon, 12 Feb 2024
Tenax Therapeutics Raises $9M in Public Offering and Warrants - TipRanks.com - TipRanks
Thu, 08 Feb 2024
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering - GlobeNewswire
Thu, 08 Feb 2024
Why Is Tenax Therapeutics (TENX) Stock Down 64% Today? - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 4 (%) |
| Shares Short | 49 (K) |
| Shares Short P.Month | 72 (K) |
| EPS | -31.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 27.14 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -68.3 % |
| Return on Equity (ttm) | -160.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.12 |
| PEG Ratio | 0 |
| Price to Book value | 0.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|